Lumos Pharma, Inc. LUMO
Set alert
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 37.54M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -2.01
- Beta
- 0.33
- Short ratio
- 0.59
- Inst. own
- 24.27%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 7, 2024
- 50-d avg
- 4.23
- 200-d avg
- 3.10
- 1y target
- 4.25
News
1 year ago globenewswire.com
Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures' Acquisition of Lumos Pharma
AUSTIN, Texas and GREENWICH, Conn., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO) (“Lumos Pharma” or the “Company”), a clinical stage biopharmaceutical company focused on…
1 year ago globenewswire.com
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Lumos Pharma Inc. – LUMO
NEW YORK, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS…
2 years ago prnewswire.com
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Lumos Pharma, Inc.
NEW YORK , Oct. 23, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Lumos Pharma, Inc. (NASDAQ: LUMO) and its board of directors concerning the proposed…
2 years ago prnewswire.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MMLP and LUMO on Behalf of Shareholders
NEW YORK , Oct. 23, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or…
2 years ago businesswire.com
LUMO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Lumos Pharma, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Lumos Pharma, Inc. (NASDAQ: LUMO) to Double Point Ventures LLC for $4.25 per share in…
2 years ago globenewswire.com
Lumos Pharma Announces Abstract Accepted for Oral Presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, APPES 2024
AUSTIN, Texas, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that an…
2 years ago globenewswire.com
Lumos Pharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference
AUSTIN, Texas, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company…
2 years ago seekingalpha.com
Lumos Pharma, Inc. (LUMO) Q2 2024 Earnings Call Transcript
Lumos Pharma, Inc. (NASDAQ:LUMO ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Lisa Miller - Vice President, Investor Relations Rick Hawkins - Chief Executive…
2 years ago globenewswire.com
Lumos Pharma Reports Second Quarter 2024 Financial Results and Provides Clinical Development Update
Following Positive End of Phase 2 Meeting with FDA, Company Continues to Advance Plans for Phase 3 Placebo-Controlled Trial of LUM-201 in Moderate Pediatric Growth Hormone Deficiency
2 years ago globenewswire.com
Lumos Pharma to Report Second Quarter 2024 Financial Results and Provide Clinical Update on August 1, 2024
AUSTIN, Texas, July 23, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, announced it will report second…
2 years ago globenewswire.com
Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024
AUSTIN, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that new…
2 years ago seekingalpha.com
Lumos Pharma, Inc. (LUMO) Q1 2024 Earnings Call Transcript
Lumos Pharma, Inc. (NASDAQ:LUMO ) Q1 2024 Earnings Conference Call May 15, 2024 8:30 AM ET Company Participants Lisa Miller - Vice President, Investor Relations Rick Hawkins - Chief Executive Officer…
2 years ago globenewswire.com
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results
Outcome from End-of-Phase 2 Meeting Supportive of a Placebo-Controlled Phase 3 Trial Updated 12 and 24-Month Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials Continue to Show Oral LUM-201…
2 years ago globenewswire.com
Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024
AUSTIN, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, announced it will report first…
2 years ago globenewswire.com
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
AUSTIN, Texas, April 18, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD)…
2 years ago globenewswire.com
Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042
AUSTIN, Texas, March 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD)…
2 years ago seekingalpha.com
Lumos Pharma, Inc. (LUMO) Q4 2023 Earnings Call Transcript
Lumos Pharma, Inc. (NASDAQ:LUMO ) Q4 2023 Earnings Conference March 7, 2024 4:30 PM ET Company Participants Lisa Miller - Vice President, IR Rick Hawkins - CEO and Chairman John McKew - President and…
2 years ago globenewswire.com
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
End of Phase 2 Meeting to Occur in Q2 2024, Initiation of LUM-201 Phase 3 Trial Expected in Q4 2024 Previously Announced Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in…
-
2 years ago benzinga.com
Earnings Scheduled For March 7, 2024
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million.
2 years ago globenewswire.com
Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024
AUSTIN, Texas, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD)…
2 years ago globenewswire.com
Lumos Pharma to Participate in Oppenheimer's 34th Annual Healthcare Life Sciences Conference
AUSTIN, Texas, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency…
-
2 years ago benzinga.com
Roblox, Under Armour, GoPro, Nuvei And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded mostly lower, with the Nasdaq Composite falling around 20 points on Wednesday. Here are some big stocks recording gains in today’s session.
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 128 companies set new 52-week lows.
-
3 years ago benzinga.com
Earnings Scheduled For August 9, 2023
Companies Reporting Before The Bell • Sony Group (NYSE:SONY) is estimated to report quarterly earnings at $0.96 per share on revenue of $18.11 billion.
-
3 years ago benzinga.com
Earnings Scheduled For March 1, 2023
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
Monday saw 196 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 64 companies achieved new lows for the year.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
OnThursday, 137 stocks made new 52-week lows.
-
4 years ago benzinga.com
Earnings Scheduled For August 9, 2022
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.
-
4 years ago benzinga.com
Earnings Scheduled For May 10, 2022
Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.
-
4 years ago benzinga.com
Earnings Scheduled For March 10, 2022
Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
During Thursday's morning trading, 152 companies set new 52-week lows.
-
4 years ago benzinga.com
Earnings Scheduled For November 3, 2021
Companies Reporting Before The Bell • R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion.
-
5 years ago benzinga.com
Earnings Scheduled For August 5, 2021
Companies Reporting Before The Bell • OneSpaWorld Holdings (NASDAQ:OSW) is projected to report quarterly loss at $0.20 per share on revenue of $6.42 million.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's morning trading, 47 companies set new 52-week lows.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
Before 10 a.m. ET Thursday, 42 stocks made new 52-week lows.
-
5 years ago benzinga.com
Earnings Scheduled For May 5, 2021
Companies Reporting Before The Bell • Monmouth Real Estate (NYSE:MNR) is likely to report earnings for its second quarter.
-
5 years ago benzinga.com
Earnings Scheduled For March 9, 2021
Companies Reporting Before The Bell • Barnes & Noble Education (NYSE:BNED) is expected to report quarterly loss at $0.38 per share on revenue of $397.48 million.
-
5 years ago benzinga.com
77 Biggest Movers From Yesterday
Gainers Synthetic Biologics, Inc. (NYSE: SYN) shares climbed 100% to close at $1.00 on Tuesday after gaining over 30% on Monday.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Highs On Wednesday
Wednesday morning saw 123 companies set new 52-week highs.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Highs On Monday
This morning 301 companies reached new 52-week highs.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Highs On Wednesday
Wednesday morning saw 335 companies set new 52-week highs.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Highs On Tuesday
During Tuesday's morning session, 342 companies made new 52-week highs.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Highs On Friday
Friday's session saw 466 companies set new 52-week highs.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Highs On Wednesday
During Wednesday's morning trading, 254 companies set new 52-week highs.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Highs On Monday
Monday's morning session saw 240 companies set new 52-week highs.
-
6 years ago benzinga.com
Stocks That Hit 52-Week Highs On Wednesday
On Wednesday, 36 stocks hit new 52-week highs.
-
6 years ago benzinga.com
Stocks That Hit 52-Week Highs On Tuesday
On Tuesday, 154 stocks made new 52-week highs.